

The following formulary equivalency* table for subcutaneous, intermittent insulin use, has been approved by Pediatric and Women’s Health endocrinology and key stakeholders. Note, this is not a therapeutic interchange, and as such, an appropriate order must be written. The right column reflects products on formulary.

*Equivalency: Equivalent in terms of dosing and pharmacokinetic properties (ie. Onset, peak, duration).

Insulin brand/type	Preparation dispensed (Equivalent insulin on IWK Formulary)
RAPID-ACTING	
HumaLOG® (lispro) 100 units/mL	HumaLOG® (lispro) 100 units/mL
Admelog (lispro) 100 units/mL	OR
NovoRAPID® (aspart) 100 units/mL	HumaLOG® (lispro) 100 units/mL (junior)
Fiasp® (aspart) 100 units/mL	
Trurapi® (aspart) 100 units/mL	
Apidra® (glulisine) 100 units/mL	Apidra® (glulisine) 100 units/mL
SHORT-ACTING	
HumuLIN R® 100 units/mL	HumuLIN R® (regular) 100 units/mL
NovoLIN Toronto® 100 units/mL	
INTERMEDIATE-ACTING	
HumuLIN N® (NPH) 100 units/mL	HumuLIN N® (NPH) 100 units/mL
NovoLIN ge NPH® 100 units/mL	
LONG-ACTING	
Lantus® (glargine) 100 units/mL	Basaglar® (glargine) 100 units/mL
Basaglar® (glargine) 100 units/mL	
Toujeo (glargine) 300 units/mL	Toujeo (glargine) 300 units/mL
Tresiba® (degludec)	Tresiba® (degludec)
• 100 units/mL	• 100 units/mL
• 200 units/mL	• 200 units/mL
Levemir® (detemir) 100 units/mL	Levemir® (detemir) 100 units/mL

Last updated: February 2022